GALC Antibody (G-6): sc-518055

GALC Antibody (G-6) is a mouse monoclonal IgG2a kappa light chain antibody that detects GALC of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). GALC (G-6) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. GALC, or galactosylceramidase, is a crucial lysosomal enzyme responsible for hydrolyzing galactose ester bonds in several galactolipids, such as galactosylceramide and lactosylceramide, which are vital components of the myelin sheath surrounding nerve cells. Proper functioning of GALC is essential for maintaining myelin integrity, as disruptions in GALC activity can lead to toxic substrate accumulation, ultimately resulting in severe neurological disorders like Krabbe disease, an autosomal recessive condition affecting approximately 1 in 150,000 infants. Mutations in the GALC gene, such as the W339X premature stop codon found in the "twitcher" mouse model, lead to complete loss of enzymatic activity and serve as a critical tool for studying the pathophysiology of this devastating disease. Alternate transcriptional splice variants of the GALC gene have been identified, encoding different isoforms that may have distinct functional roles, further emphasizing GALC′s importance in both health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

GALC Antibody (G-6) References:

1. Implications of galactocerebrosidase and galactosylcerebroside metabolism in cancer cells.  |  Beier, UH. and Görögh, T. 2005. Int J Cancer. 115: 6-10. PMID: 15657896
2. Galactosylceramidase deficiency causes sperm abnormalities in the mouse model of globoid cell leukodystrophy.  |  Luddi, A., et al. 2005. Exp Cell Res. 304: 59-68. PMID: 15707574
3. GALC transduction leads to morphological improvement of the twitcher oligodendrocytes in vivo.  |  Meng, XL., et al. 2005. Mol Genet Metab. 84: 332-43. PMID: 15781194
4. AAV-mediated expression of galactocerebrosidase in brain results in attenuated symptoms and extended life span in murine models of globoid cell leukodystrophy.  |  Rafi, MA., et al. 2005. Mol Ther. 11: 734-44. PMID: 15851012
5. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease.  |  Escolar, ML., et al. 2005. N Engl J Med. 352: 2069-81. PMID: 15901860
6. AAV2/5 vector expressing galactocerebrosidase ameliorates CNS disease in the murine model of globoid-cell leukodystrophy more efficiently than AAV2.  |  Lin, D., et al. 2005. Mol Ther. 12: 422-30. PMID: 15996520
7. Biochemical and pathological evaluation of long-lived mice with globoid cell leukodystrophy after bone marrow transplantation.  |  Luzi, P., et al. 2005. Mol Genet Metab. 86: 150-9. PMID: 16169269
8. The therapeutic potential of neural stem/progenitor cells in murine globoid cell leukodystrophy is conditioned by macrophage/microglia activation.  |  Pellegatta, S., et al. 2006. Neurobiol Dis. 21: 314-23. PMID: 16199167
9. Galactocerebrosidase-deficient oligodendrocytes maintain stable central myelin by exogenous replacement of the missing enzyme in mice.  |  Kondo, Y., et al. 2005. Proc Natl Acad Sci U S A. 102: 18670-5. PMID: 16352725
10. Platelet autophagic machinery involved in thrombosis through a novel linkage of AMPK-MTOR to sphingolipid metabolism.  |  Lee, TY., et al. 2021. Autophagy. 17: 4141-4158. PMID: 33749503
11. β-Galactosylceramidase in cancer: friend or foe?  |  Presta, M. 2021. Trends Cancer. 7: 974-977. PMID: 34456156
12. The Pro-Oncogenic Sphingolipid-Metabolizing Enzyme β-Galactosylceramidase Modulates the Proteomic Landscape in BRAF(V600E)-Mutated Human Melanoma Cells.  |  Capoferri, D., et al. 2023. Int J Mol Sci. 24: PMID: 37445731

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-GALC Antibody (G-6) has 1 citations in a variety of scientific publications.

Primary antibodies like Anti-GALC Antibody (G-6) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

GALC Antibody (G-6) Specifications

Alternate Product Name: GALC

Product Clone Name: G-6

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids: 98-120

Epitope Target: GALC

Epitope Species: human

Product Reactivity/Detection: GALC isoforms 1 and 2

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 1 citations in various scientific publications

Available Conjugates/Forms for GALC Antibody (G-6): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin